Related references
Note: Only part of the references are listed.Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial
Rodabe N. Amaria et al.
LANCET ONCOLOGY (2018)
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
Alexander M. M. Eggermont et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
The use of immunotherapy in the treatment of melanoma
Tala Achkar et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial
Paolo A. Ascierto et al.
LANCET ONCOLOGY (2017)
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
J. Weber et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma
G. V. Long et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Defining Clinical Response Criteria and Early Response Criteria for Precision Oncology: Current State-of-the-Art and Future Perspectives
Vivek Subbiah et al.
DIAGNOSTICS (2017)
Characterization of the T cell repertoire by deep T cell receptor sequencing in tissues and blood from patients with advanced colorectal cancer
Kenji Tamura et al.
ONCOLOGY LETTERS (2016)
Phenotypic and functional testing of circulating regulatory T cells in advanced melanoma patients treated with neoadjuvant ipilimumab
Janet Retseck et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2016)
Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial
Alexander M. M. Eggermont et al.
LANCET ONCOLOGY (2015)
Peripheral T cell receptor diversity is associated with clinical outcomes following ipilimumab treatment in metastatic melanoma
Michael A. Postow et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2015)
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Paul C. Tumeh et al.
NATURE (2014)
Immune Monitoring of the Circulation and the Tumor Microenvironment in Patients with Regionally Advanced Melanoma Receiving Neoadjuvant Ipilimumab
Ahmad A. Tarhini et al.
PLOS ONE (2014)
Improved Survival with T Cell Clonotype Stability After Anti-CTLA-4 Treatment in Cancer Patients
Edward Cha et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Using synthetic templates to design an unbiased multiplex PCR assay
Christopher S. Carlson et al.
NATURE COMMUNICATIONS (2013)
Immune-Mediated Adverse Events Associated with Ipilimumab CTLA-4 Blockade Therapy: The Underlying Mechanisms and Clinical Management
Ahmad Tarhini
SCIENTIFICA (2013)
Safety and Efficacy of Combination Immunotherapy With Interferon Alfa-2b and Tremelimumab in Patients With Stage IV Melanoma
Ahmad A. Tarhini et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Ultra-sensitive detection of rare T cell clones
Harlan Robins et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2012)
Neoadjuvant Therapy for High-Risk Bulky Regional Melanoma
Ahmad A. Tarhini et al.
JOURNAL OF SURGICAL ONCOLOGY (2011)
Phase II trial of neoadjuvant temozolomide in resectable melanoma patients
G. D. Shah et al.
ANNALS OF ONCOLOGY (2010)
Site and Timing of First Relapse in Stage III Melanoma Patients: Implications for Follow-Up Guidelines
Emanuela Romano et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
Jedd D. Wolchok et al.
LANCET ONCOLOGY (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Comprehensive assessment of T-cell receptor β-chain diversity in αβ T cells
Harlan S. Robins et al.
BLOOD (2009)
Preoperative chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27
Priya Rastogi et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase III Trial Comparing Concurrent Biochemotherapy With Cisplatin, Vinblastine, Dacarbazine, Interleukin-2, and Interferon Alfa-2b With Cisplatin, Vinblastine, and Dacarbazine Alone in Patients With Metastatic Malignant Melanoma (E3695): A Trial Coordinated by the Eastern Cooperative Oncology Group
Michael B. Atkins et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Multiplex analysis of serum cytokines in melanoma patients treated with interferon-α2b
Zoya R. Yurkovetsky et al.
CLINICAL CANCER RESEARCH (2007)
Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses
Stergios J. Moschos et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27
HD Bear et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Evidence-based use of neoaduvant taxane in operable and inoperable breast cancer
LG Estévez et al.
CLINICAL CANCER RESEARCH (2004)
Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer
HB Grossman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Disease-associated bias in T helper type 1 (Th1)/Th2 CD4+ T cell responses against MAGE-6 in HLA-DRB1*0401+ patients with renal cell carcinoma or melanoma
T Tatsumi et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2002)
A phase II study of neoadjuvant biochemotherapy for stage III melanoma
P Gibbs et al.
CANCER (2002)
Expression of CCR-7, MIP-3β, and Th-1 chemokines in type IIFN-induced monocyte-derived dendritic cells:: importance for the rapid acquisition of potent migratory and functional activities
S Parlato et al.
BLOOD (2001)
Preoperative chemotherapy in primary operable breast cancer: Results from the European Organization for Research and Treatment of Cancer trial 10902
JA van der Hage et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: Results of Intergroup trial E1694/S9512/C509801
JM Kirkwood et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
High- and low-dose interferon alfa-2b in high-risk melanoma: First analysis of Intergroup Trial E1690/S9111/C9190
JM Kirkwood et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Interferon-alpha (IFN-alpha) stimulates anti-melanoma cytotoxic T lymphocyte (CTL) generation in mixed lymphocyte tumour cultures (MLTC)
KJ Palmer et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2000)
Share Paper
